Personalising healthcare: Professors Andres Metspalu and Lili Milani and Dr Tõnu Esko discuss their project based on the sequencing and genotype analysis of 150,000 individuals in Estonia and its implications

Emerging personalised medicine initiatives have the perspective to cut healthcare costs and improve the overhall health of the population. Taking into account the individual's molecular characteristics complemented by environmental and lifestyle factors, will allow to develop more precise and improved disease prevention and treatment programs compared to conventional methods. As an example of potential for personalised medicine, an estimated 90% drugs are effective in only 30-50% of the population, which means that more than a third of all money spent on drugs has been ineffective. 

Research opportunities provided by the unique sources of EGC-UT Biobank, nation-wide Electronic Medical Records systemst and the Estonian National Personal Medicine Pilot project can be effectively translated into improved understanding of disease etiopathologies and clinical benefit through early diagnosis, risk stratification, treatment and management. The ePerMed project is aimed at the scientific excellence of EGC-UT in the fields on functional and statistical genomics of common and rare diseases by capitalizing on knowledge transfer from two internationally renowned partners in the field of human and medical genomics -- UNIL-CIG in Switzerland and UH-FIMM in Finland. 

As a foreseen result of the ePerMed project, EGC-UT will have the capacity to move from the current research on the genome wide association studies to advanced research of disease mechanisms and to clinical benefits through early diagnosis, reliable risk stratification and improved treatment strategies using genetic risk score (GRS) approach. Ultimately, this will enable EGC-UT to deliver effective personalised medicine across several clinically relevant phenotypic traits and diseases. As in 2018, pilot projects are on going in EGC-UT Biobank (delivering GRS to biopank participants, more than 500 have already received reports and are very satisfied) and in the two major hospital (TU Hospital and North Estonian Regional Hospital) using breast cancer and CAD as models for the entire proces.

Read more: http://www.ingentaconnect.com/content/sil/impact/2018/00002018/00000007…